Enliven Therapeutics Inc. (NASDAQ:ELVN) — Market Cap & Net Worth
Market Cap & Net Worth: Enliven Therapeutics Inc. (ELVN)
Enliven Therapeutics Inc. (NASDAQ:ELVN) has a market capitalization of $3.99 Billion ($3.99 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4133 globally and #1438 in its home market, demonstrating a -8.75% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enliven Therapeutics Inc.'s stock price $54.43 by its total outstanding shares 73270761 (73.27 Million). Also see total assets of Enliven Therapeutics Inc. for a full breakdown of the balance sheet.
Enliven Therapeutics Inc. Market Cap History: 2020 to 2026
Enliven Therapeutics Inc.'s market capitalization history from 2020 to 2026. Data shows change from $6.46 Billion to $3.99 Billion (-1.48% CAGR). Also see how efficiently does Enliven Therapeutics Inc. generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Enliven Therapeutics Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.15% | #104 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.01% | #479 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 0.21% | #67 of 263 |
Weight: Enliven Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enliven Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enliven Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ELVN live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ELVN by Market Capitalization
Companies near Enliven Therapeutics Inc. in the global market cap rankings as of September 16, 2026. Review ELVN tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Enliven Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Enliven Therapeutics Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Enliven Therapeutics Inc.'s market cap moved from $6.46 Billion to $ 3.99 Billion, with a yearly change of -1.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.99 Billion | +253.44% |
| 2025 | $1.13 Billion | -31.56% |
| 2024 | $1.65 Billion | +62.57% |
| 2023 | $1.01 Billion | -15.40% |
| 2022 | $1.20 Billion | +81.78% |
| 2021 | $659.44 Million | -89.80% |
| 2020 | $6.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Enliven Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.99 Billion USD |
| MoneyControl | $3.99 Billion USD |
| MarketWatch | $3.99 Billion USD |
| marketcap.company | $3.99 Billion USD |
| Reuters | $3.99 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversibl… Read more